Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Piperacillin Tazobactam vs Meropenem for Cephalosporin-resistant Enterobacteriaceae Bloodstream Infections
NCT03671967Phase 4Recruiting
- Sponsor
- Rambam Health Care Campus
- Start
- May 2019
- Primary completion
- Jan 2027
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 2
01
Overview
A Phase 4 trial of piperacillin + tazobactam in Bacteremia, Enterobacteriaceae infection, sponsored by Rambam Health Care Campus. Started May 2019; status: recruiting.
02
Drugs
piperacillin + tazobactam
03
Conditions
BacteremiaEnterobacteriaceae infection
Beyond the preview
Go deeper on NCT03671967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03671967.